A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions

Kirsten H. Long; Henry H. Ting; Erin K. McMurtry; Ryan J. Lennon; Douglas L. Wood; David R. Holmes; Ganesh Raveendran; Charanjit S. Rihal

doi:10.1111/j.1524-4733.2007.00257.x

A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions

Kirsten H. Long, Henry H. Ting, Erin K. McMurtry, Ryan J. Lennon, Douglas L. Wood, David R. Holmes, Ganesh Raveendran, Charanjit S. Rihal

Medicine - Cardiology Division

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Background: Although the efficacy of platelet glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa) in reducing complication rates during percutaneous coronary intervention (PCI) is well established, comparative studies assessing currently approved agents as administered in current practice are limited. We studied the clinical and length of stay (LOS) outcomes of patients undergoing PCI who received either abciximab or eptifibatide. Methods: All patients undergoing elective, urgent, or emergency PCI at Mayo Clinic Rochester between November 17, 2000 and August 31, 2004 who received either abciximab or eptifibatide were included. Clinical, angiographic, and follow-up data were prospectively recorded in the Mayo Clinic PCI Registry; administrative data recorded LOS. We used logistic and Cox proportional hazard models to estimate the risk of adverse events and generalized linear modeling to predict LOS. Propensity score and standard risk adjustments were used to account for baseline differences. Results: A total of 2123 PCI patients received eptifibatide and 951 received abciximab. The adjusted odds ratio for in-hospital death and myocardial infarction (MI) with eptifibatide was 0.80 (95% CI 0.56-1.14, P = 0.21) versus abciximab. Adjusted hazard ratios for death and MI and for death, MI, or target vessel revascularization during a median follow-up of 24.6 months were 0.84 (95% CI 0.68-1.02, P = 0.08) and 0.95 (95% CI 0.81-1.11, P = 0.53), respectively. Adjusted postprocedural LOS was similar at 3.4 days. Conclusion: This large observational study found no evidence of a clinical or LOS advantage to physician choice of either abciximab or eptifibatide during PCI in contemporary practice.

Original language	English (US)
Pages (from-to)	462-469
Number of pages	8
Journal	Value in Health
Volume	11
Issue number	3
DOIs	https://doi.org/10.1111/j.1524-4733.2007.00257.x
State	Published - 2008

Bibliographical note

Funding Information:
Financial support: This study was funded by an investigator-initiated research grant from Millennium Pharmaceuticals, Inc. The authors independently designed and conducted study analyses and preparation of the article. Sponsor representatives were allowed to review the draft. The contents of publication of the article are not subject to approval by the sponsor. Dr. Rihal has had research and consulting agreements with Millennium Pharmaceuticals, Inc. All other coauthors have no conflicts of interest directly relevant to the content of this article to disclose.

Keywords

Angioplasty
Length of stay
Platelet glycoprotein IIb/IIIa inhibitor

Access

10.1111/j.1524-4733.2007.00257.x

OpenUrl availability

Full text

Cite this

@article{54419a1cfe1f456f972fc757613f5b17,

title = "A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions",

abstract = "Background: Although the efficacy of platelet glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa) in reducing complication rates during percutaneous coronary intervention (PCI) is well established, comparative studies assessing currently approved agents as administered in current practice are limited. We studied the clinical and length of stay (LOS) outcomes of patients undergoing PCI who received either abciximab or eptifibatide. Methods: All patients undergoing elective, urgent, or emergency PCI at Mayo Clinic Rochester between November 17, 2000 and August 31, 2004 who received either abciximab or eptifibatide were included. Clinical, angiographic, and follow-up data were prospectively recorded in the Mayo Clinic PCI Registry; administrative data recorded LOS. We used logistic and Cox proportional hazard models to estimate the risk of adverse events and generalized linear modeling to predict LOS. Propensity score and standard risk adjustments were used to account for baseline differences. Results: A total of 2123 PCI patients received eptifibatide and 951 received abciximab. The adjusted odds ratio for in-hospital death and myocardial infarction (MI) with eptifibatide was 0.80 (95% CI 0.56-1.14, P = 0.21) versus abciximab. Adjusted hazard ratios for death and MI and for death, MI, or target vessel revascularization during a median follow-up of 24.6 months were 0.84 (95% CI 0.68-1.02, P = 0.08) and 0.95 (95% CI 0.81-1.11, P = 0.53), respectively. Adjusted postprocedural LOS was similar at 3.4 days. Conclusion: This large observational study found no evidence of a clinical or LOS advantage to physician choice of either abciximab or eptifibatide during PCI in contemporary practice.",

keywords = "Angioplasty, Length of stay, Platelet glycoprotein IIb/IIIa inhibitor",

author = "Long, {Kirsten H.} and Ting, {Henry H.} and McMurtry, {Erin K.} and Lennon, {Ryan J.} and Wood, {Douglas L.} and Holmes, {David R.} and Ganesh Raveendran and Rihal, {Charanjit S.}",

note = "Funding Information: Financial support: This study was funded by an investigator-initiated research grant from Millennium Pharmaceuticals, Inc. The authors independently designed and conducted study analyses and preparation of the article. Sponsor representatives were allowed to review the draft. The contents of publication of the article are not subject to approval by the sponsor. Dr. Rihal has had research and consulting agreements with Millennium Pharmaceuticals, Inc. All other coauthors have no conflicts of interest directly relevant to the content of this article to disclose.",

year = "2008",

doi = "10.1111/j.1524-4733.2007.00257.x",

language = "English (US)",

volume = "11",

pages = "462--469",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions

AU - Long, Kirsten H.

AU - Ting, Henry H.

AU - McMurtry, Erin K.

AU - Lennon, Ryan J.

AU - Wood, Douglas L.

AU - Holmes, David R.

AU - Raveendran, Ganesh

AU - Rihal, Charanjit S.

N1 - Funding Information: Financial support: This study was funded by an investigator-initiated research grant from Millennium Pharmaceuticals, Inc. The authors independently designed and conducted study analyses and preparation of the article. Sponsor representatives were allowed to review the draft. The contents of publication of the article are not subject to approval by the sponsor. Dr. Rihal has had research and consulting agreements with Millennium Pharmaceuticals, Inc. All other coauthors have no conflicts of interest directly relevant to the content of this article to disclose.

PY - 2008

Y1 - 2008

N2 - Background: Although the efficacy of platelet glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa) in reducing complication rates during percutaneous coronary intervention (PCI) is well established, comparative studies assessing currently approved agents as administered in current practice are limited. We studied the clinical and length of stay (LOS) outcomes of patients undergoing PCI who received either abciximab or eptifibatide. Methods: All patients undergoing elective, urgent, or emergency PCI at Mayo Clinic Rochester between November 17, 2000 and August 31, 2004 who received either abciximab or eptifibatide were included. Clinical, angiographic, and follow-up data were prospectively recorded in the Mayo Clinic PCI Registry; administrative data recorded LOS. We used logistic and Cox proportional hazard models to estimate the risk of adverse events and generalized linear modeling to predict LOS. Propensity score and standard risk adjustments were used to account for baseline differences. Results: A total of 2123 PCI patients received eptifibatide and 951 received abciximab. The adjusted odds ratio for in-hospital death and myocardial infarction (MI) with eptifibatide was 0.80 (95% CI 0.56-1.14, P = 0.21) versus abciximab. Adjusted hazard ratios for death and MI and for death, MI, or target vessel revascularization during a median follow-up of 24.6 months were 0.84 (95% CI 0.68-1.02, P = 0.08) and 0.95 (95% CI 0.81-1.11, P = 0.53), respectively. Adjusted postprocedural LOS was similar at 3.4 days. Conclusion: This large observational study found no evidence of a clinical or LOS advantage to physician choice of either abciximab or eptifibatide during PCI in contemporary practice.

AB - Background: Although the efficacy of platelet glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa) in reducing complication rates during percutaneous coronary intervention (PCI) is well established, comparative studies assessing currently approved agents as administered in current practice are limited. We studied the clinical and length of stay (LOS) outcomes of patients undergoing PCI who received either abciximab or eptifibatide. Methods: All patients undergoing elective, urgent, or emergency PCI at Mayo Clinic Rochester between November 17, 2000 and August 31, 2004 who received either abciximab or eptifibatide were included. Clinical, angiographic, and follow-up data were prospectively recorded in the Mayo Clinic PCI Registry; administrative data recorded LOS. We used logistic and Cox proportional hazard models to estimate the risk of adverse events and generalized linear modeling to predict LOS. Propensity score and standard risk adjustments were used to account for baseline differences. Results: A total of 2123 PCI patients received eptifibatide and 951 received abciximab. The adjusted odds ratio for in-hospital death and myocardial infarction (MI) with eptifibatide was 0.80 (95% CI 0.56-1.14, P = 0.21) versus abciximab. Adjusted hazard ratios for death and MI and for death, MI, or target vessel revascularization during a median follow-up of 24.6 months were 0.84 (95% CI 0.68-1.02, P = 0.08) and 0.95 (95% CI 0.81-1.11, P = 0.53), respectively. Adjusted postprocedural LOS was similar at 3.4 days. Conclusion: This large observational study found no evidence of a clinical or LOS advantage to physician choice of either abciximab or eptifibatide during PCI in contemporary practice.

KW - Angioplasty

KW - Length of stay

KW - Platelet glycoprotein IIb/IIIa inhibitor

UR - http://www.scopus.com/inward/record.url?scp=44249094673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249094673&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4733.2007.00257.x

DO - 10.1111/j.1524-4733.2007.00257.x

M3 - Article

C2 - 18489669

AN - SCOPUS:44249094673

SN - 1098-3015

VL - 11

SP - 462

EP - 469

JO - Value in Health

JF - Value in Health

IS - 3

ER -

A longitudinal analysis of outcomes associated with abciximab and eptifibatide in a consecutive series of 3074 percutaneous coronary interventions

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this